Forlong Biotechnology is a clinical stage biotechnology company dedicated to developing next-generation cytokine therapeutics. Based on synthetic immunology, the company has established four core technology platforms, committed to overcoming the challenges of developing cytokine drugs.

Focusing on tumor immunology, we develops engineering therapeutic cytokine combinations that act at distinct steps of the cancer-immunity cycle to treat cancer. 

Our leading asset, FL115,  is a super agonist of interleukin-15 (IL-15) that can activate natural killer (NK) cells and memory T cells. Multiple clinical trials are ongoing in both the United States and China. FL115 as a monotherapy has demonstrated good safety and initial clinical efficacy in patients with advanced solid tumors. It is the only IL-15 super agonist to achieve partial response (PR) as a monotherapy and has the potential to be the best-in-class globally. FL116 is an engineered interleukin-18 (IL-18) that targets T cells and can activate effector T cell functions. It has shown potent tumor-killing efficacy in preclinical studies of several tumor models that are resistant to immune checkpoint inhibitors (CPI).